GNOS Genosis

RNS Number:4911L
Genosis PLC
03 November 2006



For Immediate Release                                            3 November 2006



                            Genosis PLC ("Genosis")


          Positive reception for Fertell at the annual meeting of the

                   American Society of Reproductive Medicine



Genosis Inc., a wholly owned subsidiary of Genosis PLC (RIC code - GNOS), a UK
company focusing on consumer products for reproductive health, presented its
Fertell product to several hundred physicians and associated personnel at the
recent meeting of the American Society of Reproductive Medicine.


Keith Isaacson, M.D., Associate Professor of Obstetrics, Gynecology and
Reproductive Biology at Harvard Medical School said: "The advantage of Fertell
is that it specifically addresses the problems faced by couples that delay
childbearing. As a result of having this information early, patients with
abnormal tests will be able to seek fertility therapy at an earlier stage
whereby they will be much more likely to be successful."


As announced on 13th September 2006, Fertell has been accepted by the American
Pregnancy Association (APA), which has stated that "The APA's acceptance of
Fertell is based on its finding that Fertell is useful for couples seeking
information about key elements of their fertility. The APA believes that early
screening at home can be beneficial in moving forward in your attempts to
conceive."


Robert Thompson, President of Genosis, Inc said: "The positive reception of
Fertell by key opinion leaders within reproductive medicine is tremendously
encouraging. Based on recent discussions, we anticipate that, in addition to
being accepted by the APA, Fertell will be similarly acknowledged by a
nationally recognised organisation in the near future."


Genosis is in continuing discussions with a number of major retailers in the US.
It remains on track to launch Fertell nationally through key US drug chains in
Q2, 2007.



For further details, please contact:

Genosis PLC                Paul Bateman, CEO           +44 (0)20 8408 5246

Buchanan Communications    Lisa Baderoon               +44 (0)20 7466 5000
                           Rebecca Skye Dietrich




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCUUGBGGUPQGMP

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Genosis (LSE:GNOS)
Storico
Da Giu 2023 a Giu 2024